Neovacs to present full results from the Phase IIb IFNalpha Kinoid clinical study at the 13th International Lupus Congress
24 Janvier 2019 - 5:45PM
Neovacs to present full results from the Phase IIb IFNalpha Kinoid
clinical study at the 13th International Lupus Congress
PRESS
RELEASE · PRESS RELEASE
· PRESS RELEASE
NEOVACS TO PRESENT FULL RESULTS
FROM THE PHASE IIb
IFNalpha KINOID CLINICAL
STUDY AT THE 13TH INTERNATIONAL
LUPUS CONGRESS (LUPUS 2019)5 - 9
APRIL, SAN FRANCISCO
Paris & Boston, January 24th, 2019 –
17:45 pm CET - Neovacs (Euronext Growth Paris:
ALNEV), leader in active immunotherapy for the treatment
of auto-immune and inflammatory diseases announces that it has been
selected to present the results of its Phase IIb IFNα Kinoid
clinical study at the “13th International Lupus Congress (LUPUS
2019)”, to be held from 5th to 9th April in San Francisco.
Professor Frederic Houssiau, “Chairman of the
study”, will present the full results which demonstrated:
- An immune response achieved with 91% of patients treated with
IFNα Kinoid together with statistically significant efficacy in
reduction of interferon signature
- A statistically significant clinical efficacy on the LLDAS
score
- The favorable safety profile of the treatment
Based on these results, Neovacs has launched the
preparation of the Phase III clinical development program.
About Lupus Systemic lupus
erythematosus (SLE) or lupus erythematosus is a debilitating,
chronic autoimmune disease whose etiology remains unknown. SLE is
characterized by a loss of tolerance of self-antigens, with the
production of autoantibodies, especially antinuclear antibodies
that attack healthy tissues and cause inflammatory reactions in
different parts of the body. The disease can affect multiple organs
(skin, kidneys, joints, heart, lungs, central nervous system, etc.)
and is characterized by heterogeneous clinical signs (skin rashes,
arthritis, photosensitivity, nephritis, neurological disorders,
anemia, thrombocytopenia, etc.), which vary from one person to
another and change during the progression of the disease. Systemic
lupus erythematosus affects mostly women.
About IFNα
Kinoid
Neovacs anti-IFNα therapy consists of patient
immunization using Interferon α (IFNα) kinoid (IFNα Kinoid). IFNα
Kinoid is a heterocomplex consisting of an inactivated IFNα coupled
to a T-helper stimulating carrier protein, Keyhole Limpet
Hemocyanin (KLH). IFN-K is emulsified with Montanide™ oily adjuvant
that non-specifically stimulates cell-mediated immune (CMI)
responses to antigens. IFNα Kinoid elicits the production of
neutralizing polyclonal antibodies directed against the excess
IFNα, thus blocking its ability to activate the inflammatory
cascade. The generation of polyclonal neutralizing antibodies
against IFNα following the administration of IFNα Kinoid is
relevant to diseases mediated by IFNα over-production, such as
Systemic Lupus Erythematosus (SLE), Dermatomyositis (DM), Type I
Diabetes (T1D) and Sjögren’s Syndrome (SS).
About NeovacsListed on Euronext
Growth since 2010, Neovacs is today a leading biotechnology company
focused on an active immunotherapy technology platform (Kinoids)
with applications in autoimmune and/or inflammatory diseases. On
the basis of the company’s proprietary technology for inducing a
polyclonal immune response (covered by four patent families that
potentially run until 2032) Neovacs is focusing its clinical
development efforts on IFNα-Kinoid, an immunotherapy being
developed for the indication of lupus, dermatomyositis and also in
preclinical trial for Type 1 diabetes. Neovacs is also conducting
preclinical development works on other therapeutic vaccines in the
fields of auto-immune diseases, oncology and allergies. The goal of
the Kinoid approach is to enable patients to have access to safe
treatments with efficacy that is sustained in these life-long
diseases. www.neovacs.fr
Contacts
NEOVACS – Corporate Communication &
Investor RelationsCharlène Masson+33 1 53
10 93 00cmasson@neovacs.com
NEWCAP- Media
Annie-Florence Loyer +33 1 44 71 00 12 / + 33
6 88 20 35 59afloyer@newcap.fr Léa Jacquin +33 1
44 71 20 41 / +33 6 58 14 84 66ljacquin@newcap.fr
ORPHEON FINANCE – Financial
Communication and Investor RelationsJames
Palmer +33 7 60 92 77 74j.palmer@orpheonfinance.com
Neovacs (EU:ALNEV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Neovacs (EU:ALNEV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024